SHARON, Pa., May 25 /PRNewswire-FirstCall/ -- NanoLogix, Inc., (Pink Sheets: NNLX), a Nano-biotechnology company engaged in the research, development and commercialization of technologies for the production of bacteria and disease testing kits, alternative sources of fuel, and remediation of toxic materials, announced today that its DNA extraction system and protocol is both easier -- due to less steps, and quicker -- taking significantly less time than standard spin column extraction methods according to Paul Hyman, Ph.D. at Ohio State University. According to Jain PharmaBiotech, in the year 2005, the global market for molecular diagnostics will be worth $6.5 billion, representing approximately 3.3% of the total diagnostics market and approximately 14% of the in vitro diagnostic market. The molecular diagnostics market will expand to $12 billion by 2010 and $35 billion by 2015. A major portion of it can be attributed to advances in genomics and proteomics. Biochip and nanobiotechnology are expected to make a significant contribution to the growth of molecular diagnostics. Paul Hyman, Ph.D. stated, "The NanoLogix buffer allowed the DNA extraction from different strains of mycobacteria, requiring a single buffer, one incubation and one post-lysis centrifugation compared to other products, like Qiagen's QIAamp procedure, which utilizes six buffers, three incubations and four post-lysis centrifugations." The NanoLogix MycoExtract Buffer provides for the extracted DNA to be precipitated and resuspended in water. Further, the extracted DNA in the NanoLogix MycoExtract Buffer can be used directly for molecular procedures such as PCR, which also results in further time-savings. According to a BioInformatics study, nearly 84% of scientists surveyed use PCR when extracting DNA. Finally, because lysis in the NanoLogix MycoExtract Buffer is accomplished by a thirty (30) minute incubation period at 95 degrees centigrade, any unlysed cells are killed and the final steps of the procedure, as well as any down stream procedures can be done outside of a biocontainment hood. Initial applications of molecular diagnostics were mostly for infections, but are now increasing in the areas of genetic disorders, preimplantation screening and cancer. Genetic screening tests, despite some restrictions are a promising area for future expansion of in vitro diagnostic market. Molecular diagnostics is being combined with therapeutics and forms an important component of integrated healthcare. Molecular diagnostic technologies are also involved in development of personalized medicine based on pharmacogenetics and pharmacogenomics. Currently, there has been a considerable interest in developing rapid diagnostic methods for biowarfare agents such as anthrax. Clinical application of molecular technologies to elucidate, diagnose and monitor human disease has yielded over 600 diagnostic systems. PCR has revolutionized molecular diagnostics and is a method of nucleic acid analysis for producing large amounts of a specific DNA fragment. It can selectively amplify a single molecule of DNA several millionfold in a few hours. Use of this technology enables the detection and analysis of specific gene sequences in a patient's sample without cloning. Analyses can be performed on even a few cells from body fluids or even a drop of blood. Thus, PCR eliminates the need to prepare large amounts of DNA from tissue samples. According to a Frost and Sullivan report, "The development of the molecular diagnostics market, coupled with a growing number of sequencing and functional genomic initiatives have contributed to substantial expansion of the marketplace." Techniques such as cloning and peak cell rate amplification have moved out of the confines of genetics laboratories and have started being used as common research tools. Manufacturers have started to introduce microarrays that can analyze sequence variations in genes involved in drug metabolism to determine the best treatment regime. Moreover, diagnostic techniques of proven utility in disease management such as genotyping and viral load monitoring have begun to be applied in nucleic acid isolation and purification products. These emerging technologies and expanded applications of existing technologies are expected to enlarge the user base for nucleic acid isolation processes. NanoLogix is expected to benefit from this trend. About NanoLogix, Inc. NanoLogix, Inc., http://www.infectech.com , is a technology application innovator of biogas products and services designed to assist in worldwide energy independence and reduce pollution from renewable, environmentally- friendly energy sources. NanoLogix is also engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious human diseases. The Company's patents span the identification and antibiotic sensitivity testing of 34 disease-producing bacteria, including M. tuberculosis (TB), Mycobacterium avium-intracellulare (MAI), pseudomonas, and nocardia. These bacteria are cited as prominent causes of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS. Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for inducing a genetically based induction of "cell suicide" in cells. NanoLogix's patents have nanotechnology applications in medical drugs/devices, biodefense sensors, hydrogen production, cancer treatment and bioremediation. Nanotechnology applications include Biochips embedded in small transportable devices for rapid bacteria identification of disease causing pathogens, and Bio Micro Electro Mechanical Systems ("BioMEMS") for rapid environmental microbial monitoring with biodefense implications. Its hydrogen bioreactor research is designed to assist in worldwide energy independence and reduce pollution using renewable, environmentally-friendly energy sources. NanoLogix's FDA registered diagnostic test kits are designed to be used for the rapid identification of infectious human diseases and identify 34 disease-producing bacteria, including Tuberculosis (TB), Mycobacterium avium-intracellulare (MAI), Pseudomonas, and Nocardia. These bacteria are cited as prominent causes of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS, as well as in patients undergoing surgery. Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for inducing a genetically based induction of "cell suicide" in cells. It therefore serves as the foundation for cancer therapy. NanoLogix's other patents include technology designed for use in the bioremediation of contaminated soil and water. This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward- statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
SOURCE NanoLogix, Inc.